Obesity is a prominent health issue worldwide and directly impacts pancreatic health, with
obese individuals exhibiting a significant risk for increasing pancreatic ductal …

Pancreatic cancer, a prevalent malignancy of the digestive system, has a poor 5‐year
survival rate of around 10%. Although numerous minimally invasive alternative treatments …

Tumor antigens are crucial targets for T-cell-based therapy to induce tumor-specific
rejection. However, identifying pancreatic ductal adenocarcinoma (PDAC)-specific T-cell …

Metabolic reprogramming is a typical hallmark of cancer. Enhanced glycolysis in tumor cells
leads to the accumulation of lactate, which is traditionally considered metabolic waste. With …

Pancreatic ductal adenocarcinoma (PDAC)/pancreatic cancer, is a highly aggressive
malignancy with poor prognosis. Gemcitabine-based chemotherapy remains the …

Hypoxia is one of the inherent characteristics of most solid tumors; the oxygen-dependent
(O2) nature of photodynamic therapy (PDT) limits its clinical treatment against hypoxia …

Efforts to develop targetable molecular bases for drug resistance for pancreatic ductal
adenocarcinoma (PDAC) have been equivocally successful. Using RNA-seq and ingenuity …

Pancreatic cancer is a highly malignant and metastatic cancer. Pancreatic cancer can lead
to liver metastases, gallbladder metastases, and duodenum metastases. The identification of …

Simple Summary This study explores hypoxia-inducible factors (HIFs) in glioblastoma
development, progression, and treatment. Reviewing 104 relevant studies, it highlights …

Cancer-associated fibroblasts (CAFs) play an important role in a variety of cancers.
However, the role of tumor stroma in nonfunctional pancreatic neuroendocrine tumors (NF …